Sphere-9 demonstrated 73.8% freedom from AFib vs. only 65.8% observed in the control arm. AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people ...
HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life "These are excellent results for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April 8, 2024 ...
NEW YORK--(BUSINESS WIRE)--ACCESS GPO today announced a preferred, multi-year agreement with Medtronic to support availability of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Medtronic plc's Sphere-360 secured a CE mark – the second catheter in its Affera PFA franchise – as it announced completion of the first cases in its investigational device exemption HORIZON trial for ...
HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT) Breakthrough device ...
Results from the ongoing early feasibility study evaluating the Affera mapping and ablation system and the Sphere-9™ catheter for treatment of recurrent sustained monomorphic ventricular tachycardia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results